Recent 9.0% Pullback Isn't Enough to Hurt Long-term Veracyte (NASDAQ:VCYT) Shareholders, They're Still up 56% Over 1 Year

Simply Wall StFeb 14 13:31 ET

New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

BusinesswireFeb 14 08:30 ET

MYGN Stock Might Rise on Collaboration With CancerCARE

Zacks Feb 11 08:35 ET

Express News | Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 Asco Gu Symposium

ReutersFeb 11 08:30 ET

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

BusinesswireFeb 11 08:30 ET

New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients With Bladder Cancer

BusinesswireFeb 5 08:30 ET